Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nanocovax Phase 3 COVID-19 Vaccine Study
NCT04922788Phase 3Completed
- Sponsor
- Nanogen Pharmaceutical Biotechnology JSC
- Start
- Jun 2021
- Primary completion
- Jul 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Nanocovax 25 mcg with Placebo (2 arms). Primary endpoints: Number of participants who experience a first episode of virologically-confirmed COVID-19 up to 1 year, Percentage of participants reporting Serious adverse events or medically attended adverse events up to 1 year and 2 more. Started Jun 2021; status: completed.
02
Drugs
nanocovax
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04922788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04922788.